Evidence map›Paper›PMID 38288897›Full record

ArticleKorean journal of radiology2024

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [

Seunggyun Ha, Joo Hyun O, Chansoo Park, Sun Ha Boo, Ie Ryung Yoo, Hyong Woo Moon, Dae Yoon Chi, Ji Youl Lee

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean journal of radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Prostate international · 2025
    Article
  3. Article
  4. Article
  5. Comparison of novel PSMA-targeting [European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Seunggyun HaDivision of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0003-2016-1373
Joo Hyun ODivision of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ojoohyun@songeui.ac.kr.ORCID 0000-0002-6568-5915
Chansoo ParkResearch Institute of Labeling, FutureChem Co., Ltd., Seoul, Republic of Korea.ORCID 0000-0001-9150-0593
Sun Ha BooDivision of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0009-0000-8692-1668
Ie Ryung YooDivision of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0001-9738-3703
Hyong Woo MoonDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0002-9352-3411
Dae Yoon ChiResearch Institute of Labeling, FutureChem Co., Ltd., Seoul, Republic of Korea.ORCID 0000-0002-9862-3286
Ji Youl LeeDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. uroljy@catholic.ac.kr.ORCID 0000-0001-6775-1157
The Catholic University of Korea Seoul St. Mary's Hospital · KRFutureChem (South Korea) · KR

Funding

NRF 2022R1A2C1009770NRF 2022R1I1A1A01069887
6 · The paper itself

Abstract

objectiveMATERIALS AND

methodsData from 25 patients (median age, 73 years; range, 60-90) with mCRPC from a phase I study with activity escalation design of single administration of [

resultsAbsorbed dose coefficient (mean ± standard deviation) of normal organs was 1.17 ± 0.81 Gy/GBq for salivary glands, 0.05 ± 0.02 Gy/GBq for lungs, 0.14 ± 0.06 Gy/GBq for liver, 0.77 ± 0.28 Gy/GBq for kidneys, 0.12 ± 0.06 Gy/GBq for spleen, and 0.07 ± 0.02 Gy/GBq for red marrow. The absorbed dose coefficient of the tumors was 10.43 ± 7.77 Gy/GBq.

conclusion[

Indexed as

Prostatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAgedAged, 80 and overDipeptidesHumansLutetiumMaleMiddle AgedProstate-Specific AntigenTissue DistributionDipeptidesLutetiumProstate-Specific AntigenRadiopharmaceuticalsAlbuminDosimetrymCRPCPSMARadiopharmaceutical therapy

Identifiers

PMID38288897
PMCPMC10831299
OpenAlexW4391171748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.